Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8266 to 8280 of 8963 results

  1. Vandetanib for the second line treatment of non-small cell lung cancer [ID46]

    Discontinued Reference number: GID-TAG405

    Technology appraisal guidance
    Discontinued

  2. Sunitinib in combination with a taxane for the first line treatment of advanced and/or metastatic breast cancer [ID58]

    Discontinued Reference number: GID-TAG391

    Technology appraisal guidance
    Discontinued

  3. Rociletinib for previously treated EGFR T790M-positive metastatic non-small-cell lung cancer [ID883]

    Discontinued Reference number: GID-TA10045

    Technology appraisal guidance
    Discontinued

  4. Constipation (opioid induced) - lubiprostone [ID646]

    Discontinued Reference number: GID-TAG367

    Technology appraisal guidance
    Discontinued

  5. Phentermine with topiramate for the treatment of obesity and overweight [ID543]

    Discontinued Reference number: GID-TAG439

    Technology appraisal guidance
    Discontinued

  6. Laquinimod for treating relapsing-remitting multiple sclerosis [ID560]

    Discontinued Reference number: GID-TAG337

    Technology appraisal guidance
    Discontinued

  7. Lorcaserin hydrochloride for the treatment of obesity and overweight [ID337]

    Discontinued Reference number: GID-TAG420

    Technology appraisal guidance
    Discontinued

  8. Prostate cancer (hormone refractory) - atrasentan [ID390]

    Discontinued Reference number: GID-TAG379

    Technology appraisal guidance
    Discontinued

  9. Cetuximab for the treatment of advanced non-small-cell lung cancer [ID9]

    Discontinued Reference number: GID-TAG395

    Technology appraisal guidance
    Discontinued

  10. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  11. Obinutuzumab with CHOP chemotherapy for untreated CD20-positive diffuse large B-cell non-Hodgkin's lymphoma [ID1021]

    Discontinued Reference number: GID-TA11119

    Technology appraisal guidance
    Discontinued

  12. Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]

    Discontinued Reference number: GID-TA11647

    Technology appraisal guidance
    Discontinued

  13. Nitazoxanide for treating the common cold in people 12 years and over [ID4049]

    Discontinued Reference number: GID-TA11128

    Technology appraisal guidance
    Discontinued

  14. Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]

    Discontinued Reference number: GID-TA11228

    Technology appraisal guidance
    Discontinued

  15. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    Discontinued Reference number: GID-TA11086

    Technology appraisal guidance
    Discontinued